Vancomycin-Associated Nephrotoxicity

University at Buffalo

Status: Completed

Conditions: Nephrotoxicity

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01216540

IIS-000184

Details and patient eligibility

About

The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to the hospital associated with these nephrotoxic events.

Enrollment: 398 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years or older at time of hospital admission
• Had an absolute neutrophil count of ≥ 1000 cells/mm^3
• Received > 48 hours of intravenous vancomycin therapy
• Had one or more vancomycin trough levels reported within the 96 hours after therapy initiation
• Had a baseline serum creatinine level of < 2.0 mg/dL and baseline creatinine clearance level of ≥ 30 mL/min

Exclusion criteria

• Previous diagnosis of cystic fibrosis

Trial design

398 participants in 1 patient group

Patients receiving vancomycin